SCHEMBL7250903

SCHEMBL7250903

N#Cc1ccc(C(C(=O)NC2CCCCC2)C(C(N)=O)c2c[nH]c3ccccc23)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.46
RAB9A P51151 4/20 0.44
NPC1 O15118 3/20 0.44
MEN1 O00255 3/20 0.42
ALDH1A1 P00352 3/20 0.42
KMT2A Q03164 3/20 0.42
MAPT P10636 2/20 0.42
MCL1 Q07820 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
EPHX1 P07099 2/20 0.40
NR1H4 Q96RI1 1/20 0.40
NPSR1 Q6W5P4 1/20 0.38
KRAS P01116 1/20 0.38
SOS1 Q07889 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPK1 P28482 1/20 0.38
HAT1 O14929 2/20 0.37
EP300 Q09472 2/20 0.37
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7250906 0.75 MEN1 (0.54) TSHRMEN1ALDH1A1KMT2AMAPT
SCHEMBL7251407 0.69 HPGD (0.46) TSHRRAB9ANPC1MEN1ALDH1A1
SCHEMBL8348907 0.69 TSHR (0.51) TSHRRAB9ANPC1MEN1ALDH1A1
SCHEMBL17956972 0.68 STING1 (0.44) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL18648119 0.68 TSHR (0.67) TSHRRAB9ANPC1MEN1KMT2A
SCHEMBL21399726 0.67 MGAM (0.58) MEN1ALDH1A1KMT2AMAPTMCL1
SCHEMBL3996751 0.67 HPGD (0.51) RAB9ANPC1ALDH1A1KMT2AMAPT
SCHEMBL9825896 0.66 SOS1 (0.75) TSHRMEN1ALDH1A1KMT2AMAPT
SCHEMBL7646131 0.66 SOS1 (0.75) TSHRMEN1ALDH1A1KMT2AMAPT
SCHEMBL7675959 0.66 RAB9A (0.58) RAB9ANPC1MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030195212-A1 Novel melanocortin receptor agonists and antagonists MELACURE THERAPEUTICS AB (SE) 2003-10-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195212-A1 Novel melanocortin receptor agonists and antagonists MC1R, MC5R, MC4R TSHR 80/4885RAB9A 1714/4885NPC1 4060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.